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Immunoglobulin A vasculitis (IgAV; formerly Henoch Schonlein Purpura) is the most
common form of childhood vasculitis. It can occur in any age and peaks around 4–6
years old. It demonstrates seasonal variation implicating a role for environmental triggers
and geographical variation. The diagnosis is made clinically and 95% of patients will
present with a rash, together with any from a triad of other systems—gastrointestinal,
musculoskeletal, and renal. Most cases of IgAV in children have an excellent outcome.
Treatment may be required during the acute phase for gastrointestinal involvement
and renal involvement, termed IgAV nephritis (previously HSP nephritis), is the most
serious long-term manifestation accounting for ∼1–2% of all childhood end stage
kidney disease (ESKD). It therefore requires a period of renal monitoring conducted
for 6–12 months. Patients presenting with nephrotic and/or nephritic syndrome or
whom develop significant persistent proteinuria should undergo a renal biopsy to
evaluate the extent of renal inflammation and there are now international consensus
guidelines that outline the indications for when to do this. At present there is no
evidence to support the use of medications at the outset in all patients to prevent
subsequent renal inflammation. Consensus management guidelines suggest using oral
corticosteroids for milder disease, oral, or intravenous corticosteroids plus azathioprine
or mycophenolate mofetil or intravenous cyclophosphamide for moderate disease and
intravenous corticosteroids with cyclophosphamide for severe disease. Angiotensin
system inhibitors act as adjunctive treatment for persisting proteinuria and frequently
relapsing disease may necessitate the use of immunosuppressant agents. Renal
outcomes in this disease have remained static over time and progress may be hindered
due to many reasons, including the lack of reliable disease biomarkers and an absence of
core outcome measures allowing for accurate comparison between studies. This review
article summarizes the current evidence supporting the management of this condition
highlighting recent findings and areas of unmet need. In order to improve the long term
outcomes in this condition international research collaboration is urgently required.
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INTRODUCTION AND EPIDEMIOLOGY
Immunoglobulin (Ig) A vasculitis [IgAV; formerly known as
Henoch Schonlein Purpura (1)] is the most common form of
childhood vasculitis. It is a non-thrombocytopenic, small vessel
vasculitis that typically presents acutely. IgAV is by far the most
frequently encountered childhood vasculitis with an incidence of
3–27 cases per 100,000 child population (2, 3). It is therefore seen
regularly by pediatricians. It can present in any age, even during
adulthood, but it is much more frequently seen in childhood and
as such the age at peak incidence is around 4–6 years old. In
childhood-onset disease, 90% of cases occur under the age of 10
years. It is extremely rare in infants. In children, it has a slight
male predominance (1.5:1 male: female ratio) and a decreasing
incidence according to increasing age (4). Older children, mainly
teenagers with IgAV, are more likely to have disease that reflects
that of adult-onset IgAV (5). Adult onset disease differs from
childhood onset disease in terms of its manifestations with a
large comparative series describing adults rarely presenting with
abdominal pain (10 vs. 37%) and adults have higher frequency
of joint involvement when compared to children (90 vs. 44%)
(6). Longer-term outcomes are generally good and appear similar
between the two age groups (7) although smaller reports suggest
that adults are more likely to progress to end stage kidney disease
(ESKD) (8). IgAV can occur in any race and it predominates in
certain parts of the world such as Korea and Japan.
PATHOPHYSIOLOGY
Very little is understood about the exact pathophysiology of
this condition except that it is felt to be directed by abnormal
immunoglobulin A (IgA) and hence the recent change in
nomenclature (1). IgA is a major class of antibody that is present
in the mucosal secretions and it is the key first line of defense
against invasion by pathogens. In the kidney, IgAV is believed to
pathologically be related to the renal condition IgA nephropathy
(IgAN), due to the same appearances in the renal histopathology
together with elevated systemic IgA levels and circulating IgA
immune complexes, although whether they are a spectrum of the
same condition remains uncertain (9).
Elevated serum galactose-deficient IgA1 levels are seen in
IgAV (10) and abnormal IgA1 glycosylation is believed to be
a leading phenomenon in the pathophysiology. It is unknown
exactly why this occurs and it is proposed that there may
be abnormalities in the critical genes in the glycosylation
pathway like that suggested in IgA nephropathy (11). This
abnormal glycosylation results in exposure of residues, believed
to arise in the hinge region of IgA (see Figure 1), this region
then constitutes an antigen inducing a humoral autoimmune
response. Circulating immune complexes and immune deposits
contain IgA1. Galactose-deficient variants are rarely found in
normal circulatory IgA1 but are much more common in patients
with IgAV (or IgAN). It is unknown whether these are a
temporary phenomenon during the acute phase or present
even in disease quiescence. Circulating immune complexes
cannot be cleared by normal mechanisms and therefore deposit
inducing local tissue inflammation. For example, in the kidney,
FIGURE 1 | The structure of immunoglobulin A demonstrating the hinge
region where abnormalities in IgA glycosylation are believed to give rise to
antibody formation.
the transferrin receptor, which preferentially binds galactose-
deficient IgA1, is expressed on mesangial cells and binding
enhances cell proliferation, complement activation, cytokine
release, and production of extracellular matrix (ECM), all
of which contribute to renal inflammation. It is not certain
whether the pathophysiology is entirely dependent on abnormal
IgA or whether different quantities or specific abnormalities
in the various galactose-deficient regions represent phenotypic
differences in this condition.
Genetic Predisposition
The geographical variation in the incidence of this condition
highlights the potential role of genetic influences and IgAV is
more common in the Asian population (4). There have been
many genome-wide association studies that have demonstrated
the influence of mutations on the predisposition to this condition
and also in the way that the disease manifests itself; in particular
the extent of renal involvement (due to the associated long-
term renal consequences this organ has received the most
attention). It is becoming apparent therefore, that genetics plays
a key role in determining both the likelihood of getting the
condition and also the severity of the phenotype experienced.
The specific genetic risk factors for acquiring the disease
that have so far been identified include genes that code for
inflammatory pathways within the blood vessels themselves and
those coding within the kidney (see Table 1). These include genes
associated with general autoimmunity such as certain human
leucocyte antigen (HLA) alleles, together with more specific ones
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TABLE 1 | The specific genetic risk factors that have so far been identified
predisposing an individual to acquiring IgA vasculitis and those implicated in being
protective against the disease [adapted from He et al. (12)].
Genetic susceptibility Genetic protection
HLA-B*15 HLA-B*7
HLA-B*35 HLA-B*40
HLA-B*4102 HLA-B*49
HLA-B*52 HLA-B*50
HLA-A*2 HLA-A*1
HLA-A*11 HLADRB1*3
HLA-A*26 HLADRB1*7
HLA-DRB1*0103 Agtrs699M235T
HLA-DRB1*11 MEFV
HLA-DQA1*0301 PONI
HSPA21267GG
IL1815187238-137G
MCP1-2518TT
MCP1-2518T
TGF beta rs1800469-509TT
Agt
ACE
C1GALT1rs
NOS2A
eNOS
PONI192QQ
MEFV
that may influence how the vascular system responds to an
insult, for example; endothelial nitric oxide synthase (eNOS),
angiotensin-converting enzyme (ACE), interleukin 18 (IL18),
chemokine monocyte protein chemoattractant protein (MCP),
and transforming growth factor (TGF) (12). Some studies have
reported protective genetic associations that reduce the risk of
acquiring the disease, including certain HLA genes, which could
explain ethnic differences (Table 1). With regards to specific
phenotypes, most studies have focused on IgAV nephritis. The
ACE, IL8, and HLA-B∗35 genes were associated with a worse
renal phenotype (12).
It is therefore evident that this is not a condition associated
with a single common genetic mutation, rather a combination
of individual susceptibility risk factors that contribute to disease
onset and severity when combined with environmental triggers.
Environmental and Host Triggers
IgAV demonstrates seasonal tendency with fewer cases seen
during the summer months supporting the theory of viral
precipitants triggering the onset of this disease. This was nicely
demonstrated in a very large correlation study performed in
South Korea that included over 16,000 children with IgAV. The
authors looked at the seasonal variation of common viruses
with IgAV incidence and found temporal relationships with
respiratory syncytial virus (RSV), influenza and norovirus (13).
The association with viral disease may explain the tendency for
the disease to be predominantly one of childhood. As IgA arises
from the mucosal surfaces, several studies have looked at the role
of infectious foci located within the oral cavity and the ear, nose,
and throat (ENT) system. In a cohort of children in Taiwan with
IgAV, 36% were found to be positive for streptococci (14). One
relatively small study (n = 40 children with HSP) found 70%
of patients had evidence of dental caries, 53% had periodontitis,
rhinosinusitis in 19 (48%), tonsillitis in five (13%), and otitis
media in four (10%) of the 40 patients (15). An observational
drug and vaccine surveillance study (16) collected information
on drug and vaccine use in children before the onset of IgAV
from centers in Italy and concluded that the measles-mumps-
rubella (MMR) vaccine was potentially associated with a higher
risk (OR 3.4, 95% CI: 1.2–10.0) of developing IgAV. However,
a much larger, European, multicenter study (17) disputed this;
in 167 children with IgAV in a case-crossover study design,
concluded that the OR for IgAV occurring within 3 months
after vaccination was 1.6 (95% CI: 0.803.0) and hence was not
significant. The analyses was stratified according by season, year
of onset, infection, age, gender, and type and number of vaccines
received and none of the stratifications revealed any significant
associations. This suggests that vaccinations are not known to
increase the risk of IgAV and hence should not be avoided.
CLINICAL PRESENTATION
IgAV usually presents in a relatively well-child and 95% of
patients will present with a skin rash (18). In addition to the
skin findings, the condition manifests through a classical triad
of symptoms involving the gastrointestinal, musculoskeletal,
and renal systems (19). Less commonly but perhaps more
importantly, it can involve other systems such as the respiratory
or neurological, although these are very rare.
Skin Involvement
The rash is a symmetrical erythematosus petechial or purpuric
rash that almost exclusively starts on the lower limbs and
buttocks. It can include areas of bruising, usually intertwined
with the purpura, and more rarely necrotic lesions or bullae (see
Figure 2). The areas of purpura are often palpable, and the rash
may extend to involve the arms and, less commonly, the trunk.
Skin oedema can be located around the purpuric lesions. It is
very rare to get facial involvement, although it can be seen in
more severe cases but never in isolation. The diagnosis is made
clinically although confirmation by histological analysis, from
skin or renal biopsy, is sometimes helpful.
Musculoskeletal Involvement
During the acute presentation, up to 70–90% of patients will have
musculoskeletal involvement manifesting as either arthralgia or
arthritis. The frequency of arthritis is lower at around 61–64%.
Arthritis tends to have an oligo-articular pattern (4 or fewer
joints), with a predilection to joints of the lower limb. Joints of
the feet and ankles being most commonly involved followed by
knees, wrists, elbows, and hands (14, 20, 21). The rash may be co-
located in the same areas of the musculoskeletal involvement and
skin oedema can mimic a swollen joint. Joint involvement can
rarely precede skin involvement. Arthritis is usually transient and
does not cause any residual abnormalities such as joint erosions.
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FIGURE 2 | IgA vasculitis presenting in a child illustrating areas of petechiae,
purpura, bruising, and necrotic lesions on the limb (parental consent obtained).
Gastrointestinal Involvement
Gastrointestinal manifestations may precede the skin
manifestations, by a few days or a week, and this can sometimes
lead to clinical confusion until the rash appears. Gastrointestinal
(GI) tract involvement occurs in up to 72% of patients and
usually presents with colicky abdominal pain, due to bowel
angina (18). It can extend to include acute GI bleeding either
manifesting as melaena or haematemesis that can be severe and
life-threatening. Asymptomatic fecal occult blood is common
and reported in 22% of patients who weren’t thought to have
GI involvement (14). GI bleeding has been linked to the need
for a longer hospital admission (22) and in severe cases it
warrants acute immunosuppressive treatment. Intussusception
due to GI tract inflammation can also occur and this is a
surgical emergency.
Renal Involvement
Renal involvement, termed IgAV nephritis, or previously referred
to as HSP nephritis, is usually asymptomatic and thus requires
active screening. It is seen in around 40–50% of patients,
most of whom have a mild renal course that self resolves (14,
18). Microscopic haematuria is the most common finding on
urinalysis followed by proteinuria without oedema. Macroscopic
haematuria can be seen, but it is usually short-lived in the acute
phase of the disease, although some patients can evolve to have
recurrent macroscopic haematuria in a similar manner to IgA
nephropathy. IgAV nephritis can present as simple nephritis
or nephritis associated with nephrotic syndrome (oedema,
hypoalbuminaemia, and heavy proteinuria). Renal involvement
is the most serious manifestation of IgAV as it is the only organ
linked to long term morbidity and mortality in both childhood-
onset and adult-onset disease (23). There is some evidence to
suggest that patients with severe IgAV nephritis have more severe
extrarenal symptoms during the acute period although much
remains unknown about this condition (14).
Other
Testicular inflammation is seen [orchiditis occurs in 14% of
male patients (14)], presenting with pain and swelling that
may require assessment by an experienced pediatric surgeon to
exclude a testicular torsion—this distinction is important because
the management of the former is conservative, and the latter
is an acute surgical emergency (24). Central nervous system
involvement is very rare but it is described, and manifests as
seizures, weakness, confusion, visual changes, and/or reduced
conscious levels (25–28).
DIAGNOSIS AND CLASSIFICATION
During the 2012 International Chapel Hill Conference the
eponym “Henoch-Schonlein purpura (HSP)” was decided to
be replaced with IgAV based on the fact that the deposition
of the abnormal IgA in the vessel wall was the most salient
histopathological feature in this condition (1), although in
clinical practice the term HSP is still commonly used. The
1990 American College of Rheumatology criteria were the first
to attempt to develop a classification criterion for HSP. The
presence of two or more of the four criteria (palpable purpura,
the age of onset≤ 20 years, acute abdominal pain and skin biopsy
showing granulocytes in small arterioles or venules) provided
∼87% sensitivity and specificity to distinguish from other forms
of vasculitides (29). The 1990 ACR criterion was developed
from a HSP cohort of 85 patients including both children
and adults and other types of vasculitides like hypersensitivity
vasculitis which could be misclassified as HSP as they can
satisfy the two ACR criteria (purpura and biopsy findings).
Hence in 2005, a new European League Against Rheumatism
(EULAR)/Pediatric Rheumatology European Society (PReS)
classification criterion for all childhood vasculitides including
HSP was proposed based on expert consensus (30) and validated
with the support of the Pediatric Rheumatology International
Trials Organization (PRINTO) in 872 cases of HSP aged ≤ 18
years at disease onset. The EULAR/PReS/PRINTO criteria (31)
rely on clinical features and include the mandatory presence of
a vasculitic purpuric rash together with additional symptoms
and signs (Table 2) yielding an excellent sensitivity (100%) and
specificity (87%) in distinguishing HSP/IgAV from other types
of vasculitis.
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TABLE 2 | The EULAR/PReS/PRINTO classification criteria for childhood IgA
vasculitis.
Criterion Description
Mandatory Purpura or petechia with lower limb predominance
At least 1
out
of 4
(1) Acute onset diffuse abdominal colicky pain (may include
intussusception and gastrointestinal bleeding)
(2) Histology showing leukocytoclastic vasculitis or proliferative
glomerulonephritis with predominant IgA deposition.
(3) Acute onset arthralgia or arthritis
(4) Either proteinuria or haematuria
HISTOLOGICAL DIAGNOSIS AND RENAL
FOLLOW UP
Renal monitoring typically relies on regular urinalysis and
blood pressure checks. Patients with ongoing or worsening
renal inflammation should have a renal biopsy performed
to determine and grade the extent of renal inflammation.
Collaborative efforts across Europe have recently achieved
international consensus on when to perform a renal biopsy and
state that a renal biopsy should be performed if an IgA vasculitis
patient has severe proteinuria (>250 mg/mmol for at least 4
weeks; although shorter duration of severe proteinuria is also a
relative indication for biopsy); or persistent moderate (100–250
mg/mmol) proteinuria or impaired GFR. Due to the risk of long-
term renal complications, there is consensus agreement that all
patients with IgAV should have renal monitoring for at least 6
months after the acute episode, even if the initial urine is normal
(32). A normal urine microscopy is indicative of an excellent
long-term renal outcome even at day 7 but onset of renal disease
can occur at any stage, usually within the first few months.
The International Study of Kidney Disease in Children
(ISKDC) have produced histological classification criteria for
IgAV nephritis and they have a role in guiding treatment.
Features include the typical finding of a leukocytoclastic
vasculitis of the small vessels plus any of the following;
diffuse proliferation of mesangial cells and matrix without
significant involvement of capillary walls or lumina and
segmental necrotising lesions, endocapillary proliferation,
cellular crescents, and/or inflammatory infiltrate. The ISKDC
classification divides the histological appearances into six
categories (I, II, III, IV, V, and VI) (33). It is most common
to have early mesangial proliferative changes and if they are
isolated they correspond to ISKDC histological class II, if they
are combined with crescentic changes (<50%) they correspond
to class III (further subdivided into a or b for focal or diffuse
changes respectively), 50 -75% crescents are class IV and
>75% crescents are class V. Signs of chronic damage include
glomerular sclerosis, tubular loss, interstitial fibrosis, and hyaline
arteriolosclerosis. On immunofluorescence IgA is seen located in
the mesangium with variable degrees of accompanying IgG, IgM,
and C3 staining. On electron microscopy the mesangial deposits
may extend into the sub-endothelial areas and there may be
subepithelial deposits. More recently modified semi-quantitative
classification (SQC) scores have been proposed to enhance the
sensitivity in predicting the renal outcome in IgAV, these take
into account, and numerically score, certain activity, chronicity,
and tubulointerstitial renal indices (33).
TREATMENT
Most cases of IgAV in children spontaneously improve and do
not require any specific treatment except for supportive care. In
more severe cases, treatment options in part depend on the type
and severity of organ involvement. Clinical trials in this area are
sparsemaking firm evidence-based recommendations impossible
although international consensus management plans have now
been published (32).
Skin Involvement
Skin involvement is usually self-limiting and doesn’t require
specific treatment. It may require treatment when the condition
presents with a bullous or necrotic rash that jeopardizes the
skin integrity, but this is rare. Proposed treatment for severe
skin involvement suggested within the literature is based on
single case reports or small case series, with corticosteroids
recommended as the first line treatment (34–36) and should be
started as soon as the bullae or concerning necrotic areas appear.
They are usually given orally at a dose of∼1mg/kg/day. Reported
rare patients that have required adjunctive medications to control
the lesions or minimize the exposure to corticosteroids have
used Dapsone (a sulfon class of antibiotic with anti-inflammatory
actions through myeloperoxidase inhibition) or azathioprine, a
purine synthesis inhibitor.
Musculoskeletal Involvement
Management of musculoskeletal involvement is usually
supportive by providing pain relief usually using non-steroidal
anti-inflammatory medications, such as ibuprofen. More severe
cases have been reported within case series to respond to
corticosteroids at a dose similar to that proposed for severe
skin or GI disease (37). Additional immunosuppression
is rarely required for musculoskeletal disease but any of
the immunosuppressant agents including methotrexate,
hydroxychloroquine and dapsone may have a role.
Gastrointestinal Involvement
As most gastrointestinal (GI) involvement is mild and short-
lived, treatment is not usually required. GI involvement
that includes severe abdominal pain, GI hemorrhage, and/or
intussusception will necessitate intervention. Limited evidence,
suggest that abdominal pain that is not tolerable or remitting
will benefit from treatment with corticosteroids as first line
(usually oral at 1–2 mg/kg/day for ∼2 weeks then weaned) (38).
Intravenous methylprednisolone could be administered if the
condition is life-threatening, oral route is not tolerated or they
have failed to respond.
Second line treatments for GI disease described within the
literature include the use of mycophenolate mofetil (MMF)
(39), a single dose of intravenous cyclophosphamide [improved
symptoms in 6 children with steroid resistant disease (40)],
intravenous immunoglobulin IVIG [demonstrated efficacy in
6 out of 8 French children with GI pain, bleeding or
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enteropathy (41)], B cell depletion by monoclonal antibodies
(7 out of 8 children with chronic steroid dependent disease
achieved full remission) (42), methotrexate, colchicine and
hydroxychloroquine (43). A cohort of 7 children with refractory
GI bleeding that failed to respond to numerous second line
drugs reportedly responded to plasma exchange and therefore
this could be considered in severe, refractory cases (44).
Renal Involvement
Treatment of renal involvement is important because it is the
only organ associated with long term consequences. Clinical
features (such as extent of proteinuria and renal function)
combined with the renal histological appearances will facilitate
treatment choices.
Preventing Renal Inflammation
Several large randomized controlled trials (RCTs) have been
conducted in all children with IgAV focusing on the use of
corticosteroids to prevent renal inflammation, including a large
national RCT in the UK who compared oral corticosteroids to
placebo and found no difference in terms of renal outcomes
(45). The Kidney Disease: Improving Global Outcomes (KDIGO)
group systematically reviewed the available literature (46, 47) and
reported that compared to no therapy or supportive therapy,
early treatment with corticosteroids has little, or no difference
on the risk of development of kidney disease (RR 0.74, 95%CI
0.42–1.32; 5 studies, 746 participants) and little or no difference
in the development of severe kidney disease (nephrotic range
proteinuria, hypertension, or reduced kidney function) (RR 1.58,
95%CI 0.42–6.0). The Cochrane Systematic Review group have
also reviewed the available data and concluded that there is no
evidence to support the use of corticosteroids in all children with
IgAV to prevent the onset of nephritis (46, 47). Updated literature
reviews continue to demonstrate no trial data to support the use
of drugs to prevent nephritis in all children with IgAV.
Established Renal Inflammation
Immunosuppression
There is a paucity of good quality RCT’s assessing the role of
immunosuppression in the treatment of histologically proven
IgAV nephritis. The Cochrane collaboration concluded that
there is a serious lack of evidence to support treatment for
established nephritis as the research trials are few in number
and generally poor quality (47). New international consensus
guidelines have proposed treatment recommendations using
the best available evidence and recommend oral prednisolone
as first line treatment for mild renal disease (those with a
normal renal function and mild/moderate proteinuria <250
mg/mmol, this usually relates to class II, or IIIa histological
changes) and oral or intravenous prednisolone for moderate
nephritis (<50% crescents on biopsy and impaired renal function
or severe persisting proteinuria, usually histological class IIIb)
together with either azathioprine, mycophenolate mofetil or
intravenous cyclophosphamide. In severe nephritis (defined as
>50% crescents on renal biopsy and impaired renal function
or severe proteinuria >250 mg/mmol, histological class IV-V),
intravenous corticosteroids and intravenous cyclophosphamide
are recommended to induce remission followed by a period
of maintenance treatment (48). They concluded that there
doesn’t appear to be a role for calcineurin inhibitors or oral
cyclophosphamide in this disease.
Targeting the coagulation system
Abnormalities in coagulation have been implicated in the renal
pathophysiology of IgAV nephritis and as such several studies
have been conducted using inhibitors of the coagulation cascade.
The most promising of which, was a relatively large RCT, with
89 patients, using low molecular weight heparin (administered
daily over an 8-week period) alongside conventional treatment.
This demonstrated improvement in the overall outcome with
less ESKD and improvement in proteinuria (49). It is believed
that inhibition of hyperfibrinolysis may improve the renal blood
supply and hence explain the improvements that were seen.
The treatment however is invasive, requiring daily subcutaneous
injections and this hasn’t been replicated.
Targeting the angiotensin system
Due to their well-recognized role in long term renal protection,
it is consensus opinion that all patients should receive adjunctive
ACE inhibitor (ACEi) or angiotensin receptor blocker (ARBs) for
persisting proteinuria (48, 50).
Targeting B cells and plasma exchange
One small retrospective study has described the use of the
biologic agent rituximab as a method of B cell depletion. A
cohort of 8 patients with IgAV were treated with rituximab
and seemingly improved with a reduction in their steroid
requirement (42). It is worth noting however that large controlled
trials in the similar condition IgA nephropathy have been
negative, demonstrating no clinical response and that B cell
depletion by monoclonal antibodies did not influence the
galactose-deficient IgA or its antibodies (51). Extrapolating
these findings, and assuming these conditions have similar
pathophysiology, means that there is not currently an obvious
role for B cell depletion in IgAV although more mechanistic
studies are needed. On the contrary, plasma exchange has
been used during the acute phase, as a method to remove the
circulating immune complexes that occur in this disease. A
cohort of 16 children with histological class III or above IgAV
nephritis and a mean estimated glomerular filtration rate of 56
ml/min/m2 were treated with an average of 9 exchanges over 2
weeks demonstrating reported efficacy in renal parameters in 15
out of 16 patients (52). As this is an invasive procedure it is the
authors’ opinion that this should be reserved for the most severe,
unresponsive cases.
Other
There is no convincing evidence to support the use of intravenous
immunoglobulin (IVIG), montelukast, urokinase, vitamin E,
fish oil in the treatment of IgAV nephritis. Large studies are
being conducted using Chinese herbal medicines [a prospective
cohort trial is underway including 600 children, (53)] although
previous studies have demonstrated no long term differences
and their applicability with conventional medicine is uncertain.
Another potential target is the eradication of oral infections,
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using thorough dental hygiene and even tonsillectomy, and
one study reported complete recovery in all patients following
aggressive oral management (15). There are also reports of new
cases of IgAV occurring as a consequence of dental treatment;
as such the oral cavity is highly likely to be a trigger in some
patients (54). Many groups have described the beneficial role of
tonsillectomy on improving IgAV symptoms and prognosis (55–
59), albeit in uncontrolled studies. The risk: benefit ratio of this
invasive procedure remains uncertain although it may have a role
in a select group of patients. More recent studies have begun to
explore the oral microbiota and its role in IgAV pathogenesis,
where differences in the microbiota composition have been seen
when compared with healthy children (60). Similar changes
within the gut microbiome have also been reported (61).
OUTCOME
Overall the outcome is excellent in the vast majority of
children (50% have spontaneous remission) however relapses
can occur and there is a recognized risk of life-long renal
complications. The majority of children will have a self-
limiting disease course with symptoms resolving within the
first 1 month and 94% of children will make a complete
recovery by 2 years. Recurrent episodes of IgAV occur in
around 25% of patients and there is some suggestion that they
may be more common in slightly older children (aged > 8
years) and in those with nephritis (14). A study in Taiwan
demonstrated that the average time interval between the first
and second episodes was 9.2 months (62). It is the authors’
opinion that, patients presenting with a recurrent episode should
undergo renal screening again regardless of previous normal
findings and they may warrant follow up to ensure complete
remission occurs over time. In those with a relapsing course,
immunosuppressionmay be a required depending on the severity
of symptoms (63).
Unless patients present with severe neurological involvement,
which is extremely rare, early morbidity in this condition
is typically related to pain (musculoskeletal or skin) and GI
symptoms. The late morbidity is almost exclusively related to
renal involvement (IgAV nephritis).
The long-term consequences of IgAV nephritis include
chronic kidney disease (CKD) and it accounts for 1–2%
of end-stage kidney disease (ESKD) (64). Poor prognostic
features indicating a worse renal outcome include a lower
glomerular filtration rate (GFR) at presentation and those
with nephritic or nephrotic syndrome during the acute period
where the risk of progressing to some degree of chronic
kidney disease (CKD) is 41% when compared to those with
microscopic urine abnormalities (reported risk of CKD 15%)
(65, 66).
In patients who have had a renal biopsy, around a fifth of
those will continue to have significant proteinuria (>0.5 g/day)
after 10 years follow up. This does not seem to correlate to
the initial histological lesion or the treatment modality although
there is some association to a lower level of proteinuria in
patients treated with ACEi (67). In the very long term, out
of the patients who have required a renal biopsy, 66% will
maintain a normal renal function and normal urinalysis, and
21% will progress to ESRF within 20 years (68). A study with
a median of 24 years follow up in 52 patients with childhood
IgAV demonstrated additional complications with 70% of
females experiencing either proteinuria or hypertension during
pregnancy (69). Disease recurrence can occur in the transplanted
organ in patients with IgAV who undergo a renal transplant.
In a large cohort of patients from transplant centers across
Belgium and France, the reported rate of disease recurrence
was 12% with actuarial risk of graft loss in a first kidney graft
being 2.5% at 5 years and 7.5% at 10 years (70). Despite this
small but significant risk, the long-term graft outcomes are
actually very good and similar to non-IgAV transplanted patients
(71). Unfortunately, despite advances in medical science over
the past few decades, the incidence of renal complications in
IgAV hasn’t decreased over time. This was demonstrated by
a group in Japan who found no changes in the incidence of
ESKD in IgAV during the decades from 1987–1997 to 1998–
2008 (72).
RECENT ADVANCES AND AREAS OF
UNMET NEED
Recent advances highlighted in this review article include an
improvement in our understanding of the pathophysiology of
this condition that have resulted in its name change together with
knowledge that stems from large genetic susceptibility studies,
environmental population studies, and scientific exploration
of IgA abnormalities. The recent publication of international
consensus recommendations for the diagnosis and management
of this disease will significantly standardize how wemanage these
children providing a platform for future trials. Practical methods
that may reduce the severity of this condition include eradicating
potential oral triggers, such as good dental hygiene, even
considering tonsillectomy, and manipulation of the microbiota,
although the data supporting these concepts is not sufficient to
adjust clinical practice at present. This article has highlighted the
management options available for each of the organs involved
using a summary of the evidence base, consensus opinion, and
author views. The use of semi-quantitative classification
scores for the renal histological findings may produce
improvements in the correlation between initial histological
appearances and long-term renal outcome in children with
IgAV nephritis.
There are many reasons that may explain why the incidence
of ESKD in IgAV has not changed over time. One major limiting
factor has been the lack of “standard” methods to monitor or
investigate nephritis and international efforts, such as that from
the SHARE consortium, should ameliorate these limitations (32).
This is a challenging condition to study due to the high likelihood
of a spontaneous full recovery. This condition would benefit from
predefined core outcome measures for reliable comparison of
studies, as very few report critical and important outcomes, such
as all-cause mortality, time to ESKD, infection, malignancy, and
complete remission.
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Despite the majority of patients having an excellent
outcome, the renal consequences remain a concern and
poor outcomes haven’t changed. It is our opinion that the
period of renal monitoring, especially in children, provides
an ideal “window of opportunity” for early intervention if
we could stratify patients according to their risk of later
complications. Therefore improved, early biomarkers are
needed to reliably predict these patients. This condition requires
urgent international collaboration using multi-center disease
cohorts to allow discovery of novel biomarkers, validation
of clinical recommendations, and severity scores and the
development of core outcome sets. Using this set up, large scale
comparisons could be made and these will provide a setting for
well-conducted RCTs.
CONCLUSION
IgAV is a multi-systemic common childhood vasculitis. In
general, it has an excellent prognosis however there are still
patients who suffer long term, typically renal, consequences
from this condition. A multi-institutional, multi-speciality
collaborative network is needed in order to improve the
outcomes for these children with the ultimate aim to eliminate
the long-term renal consequences of IgAV.
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